ArticleCirculation research2018
Circulating Progenitor Cells and Racial Differences.
Open access · bronzeAbstract read
In one paragraph
Article in Circulation research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Racial Differences in the Effect of Granulocyte Macrophage Colony-Stimulating Factor on Improved Walking Distance in Peripheral Artery Disease: The PROPEL Randomized Clinical Trial.Journal of the American Heart Association · 2019Trial
- Injectable microsphere-based delivery strategies for stem cells and their derivatives in tissue regeneration.Bioactive materials · 2026Review
- Vein graft failure: Pathophysiology, detection, prevention and emerging therapeutic strategies.Pharmacological reviews · 2026Review
- miR-499 in Platelet-Derived Extracellular Vesicles Augments Inflammatory Cell Generation and Cardiac Remodeling After Myocardial Infarction.Circulation · 2026Article
- Declining Myocarditis Mortality in the United States and the Impact of the COVID-19 Pandemic.Journal of clinical medicine · 2025Article
- Circulating Progenitor Cells and Coronary Collaterals in Chronic Total Occlusion.International journal of cardiology · 2024Article
- Racial Health Disparity Associated With Poor Pediatric Cardiac Surgery Outcomes: A Multicentered, Cross-Sectional Study.JACC. Advances · 2024Article
- Tankyrase Inhibition Attenuates Cardiac Dilatation and Dysfunction in Ischemic Heart Failure.International journal of molecular sciences · 2022Article
- The impact of different forms of exercise on endothelial progenitor cells in healthy populations.European journal of applied physiology · 2022Review
- The innate immune response following multivalent dengue vaccination and implications for protection against dengue challenge.JCI insight · 2022Article
- Endothelial Progenitor Cells in Coronary Artery Disease: From Bench to Bedside.Stem cells translational medicine · 2022Review
- Environmental exposure to volatile organic compounds is associated with endothelial injury.Toxicology and applied pharmacology · 2022Article
- Sex-Based Differences in Autologous Cell Therapy Trials in Patients With Acute Myocardial Infarction: Subanalysis of the ACCRUE Database.Frontiers in cardiovascular medicine · 2021Article
- Association Between Change in Circulating Progenitor Cells During Exercise Stress and Risk of Adverse Cardiovascular Events in Patients With Coronary Artery Disease.JAMA cardiology · 2020Article
- Circulating Progenitor Cells and Cognitive Impairment in Men and Women with Coronary Artery Disease.Journal of Alzheimer's disease : JAD · 2020Article
Corrections and comments
- Commented on by
Authors and funding
19 authors at 2 institutions in 1 country.
Ayman Samman TahhanFrom the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine (A.S.T., M.H., H.M.K., J.H.K., P.B.S., A.A., B.K., M.M.G., M.T., S.S.H., W.T.O., M.O., I.H., V.V., A.A.Q.).
Muhammad HammadahFrom the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine (A.S.T., M.H., H.M.K., J.H.K., P.B.S., A.A., B.K., M.M.G., M.T., S.S.H., W.T.O., M.O., I.H., V.V., A.A.Q.).
Heval Mohamed KelliFrom the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine (A.S.T., M.H., H.M.K., J.H.K., P.B.S., A.A., B.K., M.M.G., M.T., S.S.H., W.T.O., M.O., I.H., V.V., A.A.Q.).
Jeong Hwan KimFrom the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine (A.S.T., M.H., H.M.K., J.H.K., P.B.S., A.A., B.K., M.M.G., M.T., S.S.H., W.T.O., M.O., I.H., V.V., A.A.Q.).
Pratik B SandesaraFrom the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine (A.S.T., M.H., H.M.K., J.H.K., P.B.S., A.A., B.K., M.M.G., M.T., S.S.H., W.T.O., M.O., I.H., V.V., A.A.Q.).
Ayman AlkhoderFrom the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine (A.S.T., M.H., H.M.K., J.H.K., P.B.S., A.A., B.K., M.M.G., M.T., S.S.H., W.T.O., M.O., I.H., V.V., A.A.Q.).
Belal KaseerFrom the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine (A.S.T., M.H., H.M.K., J.H.K., P.B.S., A.A., B.K., M.M.G., M.T., S.S.H., W.T.O., M.O., I.H., V.V., A.A.Q.).
Mohamad Mazen GafeerFrom the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine (A.S.T., M.H., H.M.K., J.H.K., P.B.S., A.A., B.K., M.M.G., M.T., S.S.H., W.T.O., M.O., I.H., V.V., A.A.Q.).
Matthew TopelFrom the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine (A.S.T., M.H., H.M.K., J.H.K., P.B.S., A.A., B.K., M.M.G., M.T., S.S.H., W.T.O., M.O., I.H., V.V., A.A.Q.).
Salim S HayekFrom the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine (A.S.T., M.H., H.M.K., J.H.K., P.B.S., A.A., B.K., M.M.G., M.T., S.S.H., W.T.O., M.O., I.H., V.V., A.A.Q.).
Wesley T O'NealFrom the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine (A.S.T., M.H., H.M.K., J.H.K., P.B.S., A.A., B.K., M.M.G., M.T., S.S.H., W.T.O., M.O., I.H., V.V., A.A.Q.).
Malik ObideenFrom the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine (A.S.T., M.H., H.M.K., J.H.K., P.B.S., A.A., B.K., M.M.G., M.T., S.S.H., W.T.O., M.O., I.H., V.V., A.A.Q.).
Yi-An KoDepartment of Biostatistics and Bioinformatics (Y.-A.K., C.L., E.M.).
Chang LiuDepartment of Biostatistics and Bioinformatics (Y.-A.K., C.L., E.M.).
Iraj HesaroiehFrom the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine (A.S.T., M.H., H.M.K., J.H.K., P.B.S., A.A., B.K., M.M.G., M.T., S.S.H., W.T.O., M.O., I.H., V.V., A.A.Q.).
Ernestine MaharDepartment of Biostatistics and Bioinformatics (Y.-A.K., C.L., E.M.).
Viola VaccarinoFrom the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine (A.S.T., M.H., H.M.K., J.H.K., P.B.S., A.A., B.K., M.M.G., M.T., S.S.H., W.T.O., M.O., I.H., V.V., A.A.Q.).
Edmund K WallerDepartment of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Arshed A QuyyumiFrom the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine (A.S.T., M.H., H.M.K., J.H.K., P.B.S., A.A., B.K., M.M.G., M.T., S.S.H., W.T.O., M.O., I.H., V.V., A.A.Q.).
Emory University · USCancer Research And Biostatistics · US
Funding
Serious Hazards of Transfusion & Cellular Therapies: Mechanisms and InterventionP01HL086773 · NHLBI · EMORY UNIVERSITY · PI ROBACK, JOHN D · 2008 to 2019
$17.9MTranslational Research Core - Engagement and Behavior ChangeP30DK111024 · NIDDK · EMORY UNIVERSITY · PI Mohammed Kumail Ali · 2016 to 2026
$13.4MVascular Responses During Mental StressP01HL101398 · NHLBI · EMORY UNIVERSITY · PI QUYYUMI, ARSHED A · 2010 to 2015
$11.0MThe role of the renin-angiotensin-endothelial pathway in ADRF1AG051633 · NIA · EMORY UNIVERSITY · PI HAJJAR, IHAB M, QUYYUMI, ARSHED A · 2015 to 2017
$6.0MMetabolomics of subclinical and clinical cardiovascular diseaseP20HL113451 · NHLBI · EMORY UNIVERSITY · PI JONES, DEAN PAUL · 2012 to 2016
$4.3MThe Emory-Morehouse Partnership to Reduce CV DisparitiesU01HL079156 · NHLBI · EMORY UNIVERSITY · PI QUYYUMI, ARSHED A · 2004 to 2008
$3.1MHypertension, angiotensin receptor blockers, and cognition: effects and mechanismR01AG042127 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HAJJAR, IHAB M · 2012 to 2017
$3.0MHeart Failure Clinical Trials NetworkU10HL110302 · NHLBI · EMORY UNIVERSITY · PI SMITH, ANDREW · 2012 to 2018
$2.5MGenome-wide association study of MI in CaucasiansR01HL089650 · NHLBI · DECODE GENETICS, INC. · PI GULCHER, JEFFREY R · 2007 to 2010
$2.3MBIOMARKERS OF ISCHEMIC OUTCOMES IN SYMPTOMATIC INTRACRANIAL STENOSIS (BIOSIS)R01NS064162 · NINDS · EMORY UNIVERSITY · PI FRANKEL, MICHAEL ROSS · 2010 to 2013
$1.0MGranulocyte-Macrophage Colony Stimulated Factor (GM-CSF) in Peripheral Arterial DiseaseR61HL138657 · NHLBI · EMORY UNIVERSITY · PI QUYYUMI, ARSHED A · 2017 to 2017
$775kNHLBI NIH HHS P01 HL086773NHLBI NIH HHS P01 HL101398NHLBI NIH HHS P20 HL113451NHLBI NIH HHS R01 HL089650NHLBI NIH HHS R61 HL138657NHLBI NIH HHS U01 HL079156NHLBI NIH HHS U10 HL110302NIA NIH HHS R01 AG042127NIA NIH HHS RF1 AG051633NIDDK NIH HHS P30 DK111024NINDS NIH HHS R01 NS064162
Abstract
rationaleBlacks compared with whites have a greater risk of adverse cardiovascular outcomes. Impaired regenerative capacity, measured as lower levels of circulating progenitor cells (CPCs), is a novel determinant of adverse outcomes; however, little is known about racial differences in CPCs.
objectiveTo investigate the number of CPCs, PC-mobilizing factors, PC mobilization during acute myocardial infarction and the predictive value of CPC counts in blacks compared with whites. METHODS AND
resultsCPCs were enumerated by flow cytometry as CD45med
conclusionsBlack subjects have lower levels of CPCs compared with whites which is partially dependent on lower circulating MMP-9 levels. Impaired regenerative capacity is predictive of adverse outcomes in blacks and may partly account for their increased risk of cardiovascular events.
Indexed as
Black or African AmericanWhite PeopleAC133 AntigenAgedAntigens, CD34BiomarkersCardiovascular DiseasesEndothelial Progenitor CellsFemaleHumansMaleMatrix Metalloproteinase 9Middle AgedReceptors, CXCR4Vascular Endothelial Growth Factor Receptor-2AC133 AntigenAntigens, CD34BiomarkersCXCR4 protein, humanMatrix Metalloproteinase 9MMP9 protein, humanPROM1 protein, humanReceptors, CXCR4Vascular Endothelial Growth Factor Receptor-2blackCD34+disparityMMP-9outcomesprogenitor cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.